Literature DB >> 17233821

Primary nodal marginal zone B-cell lymphoma: clinical features and prognostic assessment of a rare disease.

Luca Arcaini1, Marco Paulli, Sara Burcheri, Andrea Rossi, Michele Spina, Francesco Passamonti, Marco Lucioni, Teresio Motta, Vincenzo Canzonieri, Mauro Montanari, Emanuela Bonoldi, Andrea Gallamini, Lilj Uziel, Monica Crugnola, Antonio Ramponi, Francesca Montanari, Cristiana Pascutto, Enrica Morra, Mario Lazzarino.   

Abstract

This study defined the clinical features and assessed the prognosis of 47 patients (17 males, 30 females, median age 63 years) with primary nodal marginal zone B-cell lymphoma. Forty-five per cent had stage IV disease. Hepatitis C virus serology was positive in 24%. According to the Follicular Lymphoma International Prognostic Index (FLIPI), 33% were classified as low-risk, 34% as intermediate-risk, and 33% as high-risk. The 5-year overall survival (OS) was 69%. In univariate analysis worse OS was associated with: FLIPI (P = 0.02), age > 60 years (P = 0.05) and raised lactate dehydrogenase (P = 0.05). In multivariate analysis, only FLIPI predicted a worse OS (P = 0.02).

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17233821     DOI: 10.1111/j.1365-2141.2006.06437.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  13 in total

1.  Colonic mucosa-associated lymphoid tissue lymphoma identified by chromoendoscopy.

Authors:  Sang-Wook Seo; Seung-Hwa Lee; Duck-Joo Lee; Kwang-Min Kim; Joon-Koo Kang; Do-Wan Kim; Jeong-Hun Lee
Journal:  World J Gastroenterol       Date:  2014-12-28       Impact factor: 5.742

Review 2.  Non-Hodgkin lymphoma and hepatitis C: where we are and what next?

Authors:  Mihály Sulyok; Mihály Makara; Eszter Újhelyi; István Vályi-Nagy
Journal:  Pathol Oncol Res       Date:  2014-10-02       Impact factor: 3.201

Review 3.  Marginal Zone Lymphoma: Clinicopathologic Variations and Approaches to Therapy.

Authors:  Sabarish Ayyappan; Basem M William
Journal:  Curr Oncol Rep       Date:  2018-03-23       Impact factor: 5.075

4.  HCV infection, B-cell non-Hodgkin's lymphoma and immunochemotherapy: Evidence and open questions.

Authors:  Maria Christina Cox; Maria Antonietta Aloe-Spiriti; Elena Cavalieri; Eleonora Alma; Elia Gigante; Paola Begini; Caterina Rebecchini; Gianfranco Delle Fave; Massimo Marignani
Journal:  World J Gastrointest Oncol       Date:  2012-03-15

5.  Pediatric nodal marginal zone lymphoma may develop in the adult population.

Authors:  Elena Gitelson; Tahseen Al-Saleem; Valentin Robu; Michael M Millenson; Mitchell R Smith
Journal:  Leuk Lymphoma       Date:  2010-01

Review 6.  Recognizing nodal marginal zone lymphoma: recent advances and pitfalls. A systematic review.

Authors:  Michiel van den Brand; J Han J M van Krieken
Journal:  Haematologica       Date:  2013-07       Impact factor: 9.941

Review 7.  Indolent B-cell lymphomas associated with HCV infection: clinical and virological features and role of antiviral therapy.

Authors:  Luca Arcaini; Michele Merli; Stefano Volpetti; Sara Rattotti; Manuel Gotti; Francesco Zaja
Journal:  Clin Dev Immunol       Date:  2012-08-26

Review 8.  Benign and Malignant Hematological Manifestations of Chronic Hepatitis C Virus Infection.

Authors:  Shiksha Kedia; Vijaya Raj Bhatt; Sandeep Kumar Rajan; Pavan Kumar Tandra; Radwa A El Behery; Mojtaba Akhtari
Journal:  Int J Prev Med       Date:  2014-12

9.  Early, Isolated Duodenal Mucosa-Associated Lymphoid Tissue Lymphoma Presenting without Symptoms or Grossly Apparent Endoscopic Lesions and Diagnosed by Random Duodenal Biopsies.

Authors:  Mihajlo Gjeorgjievski; Issa Makki; Pradeep Khanal; Mitual B Amin; Ann Marie Blenc; Tusar Desai; Mitchell S Cappell
Journal:  Case Rep Gastroenterol       Date:  2016-06-27

Review 10.  Antiviral therapy of hepatitis C as curative treatment of indolent B-cell lymphoma.

Authors:  Michele Merli; Giuseppe Carli; Luca Arcaini; Carlo Visco
Journal:  World J Gastroenterol       Date:  2016-10-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.